HLS Therapeutics, a Canadian specialty pharmaceutical company, has received regulatory approval to expand its ongoing share repurchase program. The Toronto Stock Exchange (TSX) accepted an amendment to the company's normal course issuer bid (NCIB), raising the maximum number of shares HLS can buy back to about 1.87 million, or roughly 10% of its public float.
A share buyback, also known as a share repurchase, is a process where a company uses its own cash to buy shares from the open market. These shares are typically cancelled, which reduces the total number of shares outstanding. This can increase the value of remaining shares and is often seen as a signal that management believes the stock is undervalued.
What is a normal course issuer bid?
In Canada, a normal course issuer bid is a formal program that allows a publicly traded company to repurchase its own shares, subject to regulatory approval. The TSX sets limits on how many shares can be bought back under such a plan, usually based on a percentage of the company's public float—the shares available for trading by the public.
HLS's original NCIB allowed for the repurchase of about 1.5 million shares. The amended plan increases that cap to approximately 1.87 million shares, calculated based on the company's public float as of June 12, 2026. The company has already bought back about 1.05 million shares under the program, leaving roughly 0.82 million shares of remaining capacity.
The TSX's approval suggests the exchange is comfortable with the expanded buyback, which gives HLS more flexibility to return capital to shareholders. Companies often use buybacks when they have excess cash and believe their stock is trading below its intrinsic value.
Why this matters for investors
For everyday investors, a share buyback can be a positive signal. By reducing the number of shares outstanding, each remaining share represents a larger ownership stake in the company. This can boost earnings per share (EPS) and, all else being equal, support the stock price over time.
However, buybacks are not without criticism. Some argue that companies should use cash for growth investments or dividends instead. Others note that buybacks can sometimes be used to prop up the stock price artificially. Still, in HLS's case, the move suggests management is confident in the company's financial position and sees value in its own shares.
Investors should also consider the broader context. HLS Therapeutics focuses on commercializing products for the treatment of central nervous system disorders and other specialty areas. The company's stock performance will depend on its product pipeline, sales execution, and overall market conditions, not just the buyback.
For those watching the Canadian market, this news comes amid a period of mixed global sentiment. While some markets have seen volatility due to geopolitical tensions and interest rate concerns, individual company actions like this can still drive stock-specific moves. For example, stocks are bracing for a familiar Fed hike hangover as rates climb, which could affect investor sentiment broadly.
HLS's decision to expand its buyback is a reminder that companies can take steps to support their share price even in uncertain times. For investors, it's worth watching whether the company follows through on the remaining repurchases and how that affects the stock's performance.
What to watch next
Investors will likely monitor HLS's future announcements regarding the pace of buybacks and any updates on its business operations. The company's ability to execute its strategy and grow revenue will be key to long-term shareholder value.
While the expanded buyback provides a floor of support, it's not a guarantee of future returns. As always, investors should consider their own financial goals and risk tolerance before making any decisions.
For more on how buybacks and other corporate actions can impact markets, check out our coverage of China stocks slipping despite a trade truce and India stocks sliding on oil and insurance fears.
